PremalHarishThakerMD
Obstetrics & Gynecology • Saint Louis, MOGynecologic Oncology
Professor, Obstetrics & Gynecology, David G. And Lynne Mutch Distinguished Professor, Washington University School of Medicine
Dr. Thaker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-3181Fax+1 314-362-2893
Summary
- I am an Associate Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University in St. Louis, Missouri as well as a Clinician and a Research Member at the Siteman Cancer Center of Washington University. I trained as a cancer biologist during my fellowship at MD Anderson Cancer Center with emphasis in cell and molecular biology including angiogenesis and invasion in ovarian cancer. Now I am interested in novel therapeutics in all gynecologic cancers and have led national as well as institutional clinical trials in ovarian, cervical, and endometrial malignancies. Currently, I run our Division’s clinical trial research efforts.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2006
University of TexasMS, Cancer Biology, 2004
University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1999 - 2002
Drexel University College of Medicine/Hahnemann University HospitalResidency, Obstetrics and Gynecology, 1997 - 1999- MCP-Hahnemann College of MedicineClass of 1997, MD
- Villanova UniversityBA, Biology, 1995
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2006 - 2026
TX State Medical License 2003 - 2016
PA State Medical License 1998 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Outstanding Publication Award for 2016 of an NRG Oncology Publication on cervical cancer in Annals of Oncology 2017
- Certificate of Excellence in Reviewing Editors of Gynecologic Oncology and Gynecologic Oncology Case Reports, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Join now to see all
Clinical Trials
- A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors Start of enrollment: 2008 Oct 01
- Biobehavioral-Cytokine Interactions in Ovarian Cancer
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope
Nature Medicine. 2025-03-05 - Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer ...Paulina J Haight, Marilyn Sanchez, Samantha M Thomas, Carson Smitherman, Casey Cosgrove
Gynecologic Oncology. 2025-02-21 - Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.Ayesha B Alvero, Sharon Wu, Alex Farrell, Seongho Kim, John J Wallbillich
Gynecologic Oncology. 2025-02-18
Journal Articles
- Modified Frailty Index Is Predictive of Wound Complications in Obese Patients Undergoing Gynecologic Surgery via a Midline Vertical IncisionPremal Thaker, MD, Gynecologic Oncology
- Life Stress as a Risk Factor for Sustained Anxiety and Cortisol Dysregulation During the First Year of Survivorship in Ovarian CancerAnil K Sood, Premal H Thaker, Laila Dahmoush, Cancer
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Join now to see all
Press Mentions
Celsion Corporation (NASDAQ:CLSN) Presents A Poster Highlighting Its Phase I and II OVATION 2 Clinical Trial in Advanced Ovarian Cancer with GEN-1 at A VAM on Women’s CancerApril 20th, 2021- Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to Be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s CancerMarch 2nd, 2021
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging OpportunitiesAugust 9th, 2019- Join now to see all
Committees
- Member, Ovarian Committee, NRG Oncolgoy Group 2011 - 2018
- Member, Phase I Committee, NRG Oncology Group 2007 - 2018
Research History
- Biobehavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance2016 - 2020
- Leading Academic Participating SitesThe goal of this project is to improve patient accrual to clinical trials at NCI designated cancer centers.2014 - 2019
- Gynecologic Oncology Support fundThe goal of the project is to support research in ovarian cancer targeting the identification of clinically relevant targets in ovarian cancer.2017 - 2018
- Molecular Oncology Training GrantI serve as a clinical mentor to Ph.D. students in order for them to better understand how to translate bench findings in clinical problems.2005 - 2018
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
